Researcher
Mourad Gumusboga
Affiliations
- Mycobacteriology (Research unit)
Member
From1 Jan 2003 → Today
Projects
1 - 2 of 2 results
- Novel High-Dose Tuberculosis Retreatment Regimens: How to overcome resistance without creating more?From1 Oct 2018 → Today
- Institutional strengthening of the Mycobacteria Reference Laboratory (LRM, Bénin) for quality services and better quality of health care for Mycobacteria and other clinical bacteria, at National and Regional Level.From1 Jan 2018 → 31 Dec 2018
Publications
1 - 10 of 17 results
- Finding the right balance between efficacy and tolerability for TB treatment: the search continues(2021)
Authors: A.K.J. Maug, M A Hossain, G Mourad, Tom Decroo, Wim Mulders, Sofie Braet, Jozefien Buyze, D A Jiménez, Céline Schurmans, Natacha Herssens, et al.
Pages: 84-86Number of pages: 3 - First-line tuberculosis treatment with double-dose rifampicin is well tolerated(2020)
Authors: A.K.J. Maug, M A Hossain, Mourad Gumusboga, Tom Decroo, Wim Mulders, Sofie Braet, Jozefien Buyze, Diana Arango, Céline Schurmans, Natacha Herssens, et al.
Pages: 499-505Number of pages: 7 - Injectables' key role in rifampicin-resistant tuberculosis shorter treatment regimen outcomes(2020)
Authors: Tom Decroo, Aung Kya Jai Maug, Mohamed Anwar Hossain, Cécile Uwizeye, Mourad Gumusboga, Tine Demeulenaere, Nimer Ortuno-Gutierrez, Bouke C de Jong, Armand Van Deun
Pages: e0238016Number of pages: 11 - Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance(2019)
Authors: Gabriela Torrea, Kamela Charmaine Sy Ng, Armand Van Deun, Emmanuel André, Justine Kaisergruber, Willy Ssengooba, Christel Desmaretz, Siemon Gabriëls, Michèle Driesen, Maren Diels, et al.
Pages: 11826 - Twenty years of rifampicin resistance surveillance in Bangladesh: periodic vs. continuous monitoring(2018)
Authors: Armand Van Deun, K J M Aung, M A Hossain, M. A. H. Salim, Mourad Gumusboga, Bouke C de Jong, Tom Decroo
Pages: 1450-1461Number of pages: 13 - Specific gyrA gene mutations predict poor treatment outcome in MDR-TB(2016)
Authors: Leen Rigouts, Nele Coeck, Mourad Gumusboga, Pim De Rijk Willem, K J M Aung, M A Hossain, Kristina Fissette, H L Rieder, Conor Meehan, Bouke de Jong, et al.
Pages: 314-323Number of pages: 10 - Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients(2015)
Authors: Armand Van Deun, K J M Aung, A Hossain, Pim De Rijk Willem, Mourad Gumusboga, Leen Rigouts, Bouke de Jong
Pages: 185-190Number of pages: 6 - An operational study comparing microscopes and staining variations for tuberculosis LED FM(2014)
Authors: Armand Van Deun, K J M Aung, M H Khan, Bouke de Jong, Mourad Gumusboga, M A Hossain
Pages: 964-971Number of pages: 8 - Rifampicin resistance missed in automated liquid culture system for Mycobacterium tuberculosis with specific rpoB-mutations(2013)
Authors: Leen Rigouts, Mourad Gumusboga, Pim De Rijk Willem, Elie Nduwamahoro, Cécile Uwizeye, Bouke de Jong, Armand Van Deun
Pages: 2641-2645Number of pages: 5 - Rifampicin drug resistance tests for tuberculosis: challenging the gold standard(2013)
Authors: Armand Van Deun, A.K. Maug, V. Bola, R. Lebeke, M.A. Hossain, Pim De Rijk Willem, Leen Rigouts, Mourad Gumusboga, Gabriela Torrea, Bouke de Jong
Pages: 2633-2640Number of pages: 8